The impact of Alzheimer’s disease (AD) on caregivers, communities, and social service needs is profoundly larger than its impact on direct medical costs, as shown through financial and public health data. These impacts are interwoven with socioeconomic and racial disparities for patients and caregivers. Traditional value assessment models fail to fully consider the full scope of value for AD treatment. This observation is not new, but has been raised by many others. In light of upcoming clinical development review and value assessment of several AD therapies, the Alliance for Aging Research engaged consultants from Milliman to develop a framework of useful principles for valuing the burden of AD and potential treatments. Although this report is not quantitative, it identifies how notions of value could be quantified. Read the article.
